MedDataX Logo

Relationship Between Topiramate Use and Ocular Angle Status

NCT ID: NCT00153699

Last Updated: 2007-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We test the hypothesis whether topiramate narrows the angles which may render Asians more likely to suffer from acute angle closure glaucoma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Topiramate is approved for the treatment of epilepsy and prophylaxis of migraine attacks. There were case reports of acute angle closure glaucoma (AACG) associated with its use. AACG is particularly common in Asians because of a higher prevalence of narrow angle., we test the hypothesis whether topiramate narrows the angles which may render them more likely to suffer from AACG.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma, Angle-Closure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Side effects Topiramate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Topiramate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants aged 18-75 with an indication for starting topiramate.

Exclusion Criteria

* Patients with known allergy or intolerance to topiramate.
* Recent exposure to topiramate (\<3 months).
* Moderate to severe renal failure.
* Known history of renal calculi or hepatic failure
* Inability to give informed consent.
* Pregnant women or women of child-bearing age who do not practise an acceptable means of contraception.
* Patients known to have angle-closure glaucoma.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hong Kong Eye Hospital

OTHER

Sponsor Role collaborator

Chinese University of Hong Kong

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dexter YL Leung, MRCS

Role: PRINCIPAL_INVESTIGATOR

Hong Kong Eye Hospital

Howan Leung, MRCP

Role: PRINCIPAL_INVESTIGATOR

Chinese University of Hong Kong

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hong Kong Eye Hospital

Kowloon, , Hong Kong

Site Status

Prince of Wales Hospital

Shatin, , Hong Kong

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hong Kong

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRE-2004.310

Identifier Type: -

Identifier Source: org_study_id

NCT00518063

Identifier Type: -

Identifier Source: nct_alias